These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 28758224)

  • 1. A method to address between-subject heterogeneity for identification of principal surrogate markers in repeated low-dose challenge HIV vaccine studies.
    Spieker AJ; Huang Y
    Stat Med; 2017 Nov; 36(25):4071-4080. PubMed ID: 28758224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A discrete-time survival model with random effects for designing and analyzing repeated low-dose challenge experiments.
    Kang C; Huang Y; Miller CJ
    Biostatistics; 2015 Apr; 16(2):295-310. PubMed ID: 25190513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Likelihood-based methods for evaluating principal surrogacy in augmented vaccine trials.
    Liu W; Zhang B; Zhang H; Zhang Z
    Stat Methods Med Res; 2017 Apr; 26(2):984-996. PubMed ID: 25549966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogates of protection in repeated low-dose challenge experiments.
    Long DM; Hudgens MG; Wu CD
    Stat Med; 2015 May; 34(10):1747-60. PubMed ID: 25628249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and estimation for evaluating principal surrogate markers in vaccine trials.
    Huang Y; Gilbert PB; Wolfson J
    Biometrics; 2013 Jun; 69(2):301-9. PubMed ID: 23409839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing biomarkers as principal surrogate endpoints.
    Huang Y; Gilbert PB
    Biometrics; 2011 Dec; 67(4):1442-51. PubMed ID: 21517791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
    Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
    J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling.
    Huang Y
    Biometrics; 2018 Mar; 74(1):27-39. PubMed ID: 28653408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating candidate principal surrogate endpoints.
    Gilbert PB; Hudgens MG
    Biometrics; 2008 Dec; 64(4):1146-54. PubMed ID: 18363776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the surrogacy of multiple vaccine-induced immune response biomarkers in HIV vaccine trials.
    Dasgupta S; Huang Y
    Biostatistics; 2021 Apr; 22(2):421-436. PubMed ID: 31631216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of primate models for AIDS.
    Haigwood NL
    AIDS Rev; 2004; 6(4):187-98. PubMed ID: 15700617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calibration weighted estimation of semiparametric transformation models for two-phase sampling.
    Fong Y; Gilbert P
    Stat Med; 2015 May; 34(10):1695-707. PubMed ID: 25648332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SENSITIVITY ANALYSIS FOR EVALUATING PRINCIPAL SURROGATE ENDPOINTS RELAXING THE EQUAL EARLY CLINICAL RISK ASSUMPTION.
    Huang Y; Zhuang Y; Gilbert P
    Ann Appl Stat; 2022 Sep; 16(3):1774-1794. PubMed ID: 37008748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonparametric estimation of the joint distribution of a survival time subject to interval censoring and a continuous mark variable.
    Hudgens MG; Maathuis MH; Gilbert PB
    Biometrics; 2007 Jun; 63(2):372-80. PubMed ID: 17688489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining biomarkers for classification with covariate adjustment.
    Kim S; Huang Y
    Stat Med; 2017 Jul; 36(15):2347-2362. PubMed ID: 28276080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing treatment effects with surrogate survival outcomes using an internal validation subsample.
    Zee J; Xie SX;
    Clin Trials; 2015 Aug; 12(4):333-41. PubMed ID: 25976869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of predictive markers of HIV disease progression in vaccine trials.
    Gurunathan S; Habib RE; Baglyos L; Meric C; Plotkin S; Dodet B; Corey L; Tartaglia J
    Vaccine; 2009 Mar; 27(14):1997-2015. PubMed ID: 19200450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.
    Regoes RR; Longini IM; Feinberg MB; Staprans SI
    PLoS Med; 2005 Aug; 2(8):e249. PubMed ID: 16018721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.
    Qin L; Gilbert PB; Follmann D; Li D
    Ann Appl Stat; 2008 Mar; 2(1):386-407. PubMed ID: 19079758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.